結(jié)核病是由結(jié)核分枝桿菌復(fù)合群引起的傳染性疾病，是全球主要的流行病種之一。利福平是當(dāng)前最主要的一線抗結(jié)核藥物，因其長(zhǎng)期應(yīng)用和不規(guī)范治療，利福平耐藥逐漸增加，利福噴丁、利福布汀等利福霉素類(lèi)衍生物在抗結(jié)核治療方面起到了重要作用。基于利福霉素類(lèi)藥物的藥理及藥動(dòng)學(xué)特性，對(duì)該類(lèi)藥物在結(jié)核病治療中進(jìn)行最優(yōu)用藥選擇分析，并對(duì)該類(lèi)藥物與其他抗結(jié)核藥物聯(lián)用進(jìn)行綜述，旨在為利福霉素類(lèi)抗結(jié)核藥物的臨床用藥提供文獻(xiàn)依據(jù)。

Tuberculosis is an infectious disease caused by the mycobacterium tuberculosis complex, and is one of the major epidemic diseases in the world. Rifampicin is currently the most important first-line anti-TB drug. Due to its long-term application and non-standard treatment, it has became one of the major epidemics in the world. The cases of multidrug-or rifampicin-resistant tuberculosis increase gradually, and rifampicin derivatives (rifapentine and rifabutin) play an important role in antituberculosis treatment. Based on the pharmacological and pharmacokinetic characteristics of rifamycin, the optimal selection of rifamycin in the treatment of tuberculosis was analyzed, and the combination of rifamycin with other anti-tuberculosis drugs was reviewed. the purpose of this paper is to provide literature basis for the clinical use of rifamycin anti-tuberculosis drugs.

R978.3

福建省感染病臨床重點(diǎn)專(zhuān)科建設(shè)項(xiàng)目；福州市感染性疾病醫(yī)學(xué)中心建設(shè)項(xiàng)目（2018080306）